

Mindray ToRCH* Panel


Toxo IgG, Toxo IgM, RV IgG, RV IgM, CMV IgG, and CMV IgM




Application

ToRCH Infections


ToRCH is the acronym for (T)oxoplasmosis, (O)ther Agents, (R)ubella, (C)omegalovirus, and (H)erpes Simplex. ToRCH infections may cause illness in pregnant women and may cause birth defects in their newborns depending on the stage of pregnancy when the mother is infected. The ToRCH serology test is usually used to screen for two different antibodies to these infections: immunoglobulin G (IgG) and immunoglobulin M (IgM).



Clinical scenarios



The ToRCH serology test is usually conducted on pregnant women who have been exposed to certain infectious diseases and newborns who have congenital abnormalities that may be caused by an infection with one of these organisms.



Infection department

In the infection department, patients will get a ToRCH test to identify reasons for the infection.



Transplantation department

In the transplantation department, it is common practice to test patients for CMV before and after surgery to avoid and monitor CMV infection.



Respiratory department

Dermatology


In the respiratory or dermatology department, some doctors may advise patients with allergic symptoms to get a CMV test.

Susceptible populations

Since infection during pregnancy will introduce the risk of mother-to-child infection and lead to congenital infection in infants, early screening during pregnancy is important to prevent transmission to the fetus.

Women who are preparing pregnancy are supposed to take serologic tests. If they are diagnosed with an acute Toxo infection, they should be counseled to wait before attempting to become pregnant.

Pregnant women and those preparing pregnancy



ToRCH infections can cause a range of diseases in immunosuppressed populations. If not treated in time, they can lead to adverse fetal outcomes, and even life-threatening infections in those who are HIV positive.

Therefore, it is necessary for immunosuppressed populations to undergo ToRCH tests periodically.

Immunosuppressed populations




If a woman becomes infected with ToRCH during her pregnancy, the baby may also become infected. In this case, ToRCH tests can be conducted to check for several different infections in a newborn.

Neonates



It is important to test the patient for CMV before the transplant surgery. This is because CMV negative patients have a better prognosis. For transplant patients and their donors tested positive for CMV, the physicians will strengthen anti-virus prophylaxis, and monitor CMV status more regularly after surgery. CMV infection can be troublesome to transplant patients after surgery since it may induce rejection reactions. Therefore, it is suggested that patients should get a CMV test if they have typical CMV infected symptoms.

Transplant patients and their donors



Guidelines for ToRCH Screening During Pregnancy

Toxo, CMV, RV	
IgG-, IgM-	<ol style="list-style-type: none"> 1. Can get pregnant if not infected; 2. Dynamic monitoring of IgG and IgM in early pregnancy. Once positive, prenatal diagnosis should be carried out.
IgG+, IgM-	<ol style="list-style-type: none"> 1. Past infected women can get pregnant; 2. Recurrent infection and reinfection (CMV, RV) should be paid attention to during pregnancy, especially in the first trimester. If there is a quadruple increase in serum IgG+ in consecutive duplicates, the likelihood of recurrent infection is greater.

IgG-, IgM+

1. May be acute infection;
2. May also be false positives for IgM or long-term lasting IgM positive;
3. Review or send to a reference laboratory after 2 weeks. If the IgG turns positive, it is an acute infection, and the pregnancy is postponed for those who are not pregnant. For those who are pregnant, whether the fetus is infected should be determined (estimated gestational age or prenatal diagnosis). If the IgG does not turn positive, it is not an acute infection and IgM result is considered to be false positive.

IgG+, IgM+

1. For Toxo, it may be a current infection, and for other viruses, it may be during reinfection period. Send to reference laboratory for confirmation.
2. IgM may be false positive or long-term lasting positive. IgG avidity test should be added and re-check whether IgG is four-fold increased in consecutive double serums.
3. If it is an acute infection, postpone the pregnancy. Prenatal diagnosis can be conducted according to advice of the physician.


Mindra provides reliable ToRCH screening assays

Interpretation of test results

High precision

After the body is infected, serological and antibody changes of toxoplasma, rubella virus and cytomegalovirus vary. In such situation, in order to make correct judgement, it is required to quantify the degree of change in the antibody.

• Good onboard stabilit



• Wide detection range

Item	Toxo IgG	Rubella IgG	CMV IgG
Detection Range	0.50 IU/mL - 200.00 IU/mL	1.00 IU/mL - 350.00 IU/mL	0.30 IU/mL - 60.00 IU/mL

Mindra 's ToRCH IgG assa s provide a wide detection range and a 10-time auto-dilution expanding the reportable range, making the detection of increased IgG levels easier.

Mindra provides eas -to-use ToRCH kits

Support diverse sample types

- 3 t pes of serum collection tubes: No additive tube, Pro-coagulation tube, Gel and clot activator tube
- 4 t pes of plasma collection tubes: EDTA, Sodium Heparin, Lithium Heparin, Sodium Citrate

Multiple quality controls

- Onl 3 control products are required for the whole panel: 1 negative control for all 6 assa s, 1 positive control for the 3 IgG assa s, and 1 positive control for the 3 IgM assa s.

Low sample volume

- Onl 53 L of sample volume is required for the 6 assa s combined, which is friendl to newborns and infants.

Product Information

Order Information

• Assa kits

Full Name	Abbreviation	P/N	Package	P/N	Package
Toxoplasma gondii IgG (CLIA)	Toxo IgG	105-012527-A0	2*50 T/Kit	105-012528-A0	2*100 T/Kit
Toxoplasma gondii IgM (CLIA)	Toxo IgM	105-012533-A0	2*50 T/Kit	105-012534-A0	2*100 T/Kit
Rubella Virus IgG (CLIA)	RV IgG	105-012521-A0	2*50 T/Kit	105-012522-A0	2*100 T/Kit
Rubella Virus IgM (CLIA)	RV IgM	105-012515-A0	2*50 T/Kit	105-012516-A0	2*100 T/Kit
C. tomealovirus IgG (CLIA)	CMV IgG	105-012539-A0	2*50 T/Kit	105-012540-A0	2*100 T/Kit
C. tomealovirus IgM (CLIA)	CMV IgM	105-012545-A0	2*50 T/Kit	105-012546-A0	2*100 T/Kit

*Calibrator is included in the kit package.
Mindray HSV kit is under development

Controls

Full Name	P/N	Package	P/N	Package
ToRCH IgG/IgM Negative Control	105-024824-A0	1 3.0 mL/vial	105-024825-A0	3 3.0 mL/vial
	105-024826-A0	3 1.0 mL/vial	105-024827-A0	6 1.0 mL/vial
ToRCH IgG Positive Control	105-024832-A0	1 3.0 mL/vial	105-024833-A0	3 3.0 mL/vial
	105-024834-A0	3 1.0 mL/vial	105-024835-A0	6 1.0 mL/vial
ToRCH IgM Positive Control	105-024840-A0	1 3.0 mL/vial	105-024841-A0	3 3.0 mL/vial
	105-024842-A0	3 1.0 mL/vial	105-024843-A0	6 1.0 mL/vial

References

[1] Monto a, Jose G, and J. S. Remington. "Clinical Practice: Management of Toxoplasma gondii Infection during Pregnanc ." Clinical Infectious Diseases 47.4(2008):554-566.

[2] A, T. La arotto, et al. "Update on the prevention, diagnosis and management of c. tomealovirus infection during pregnanc ." Clinical Microbiolog and Infection 17. 9(2011):1285-1293.

[3] C. tomealovirus, parvovirus B19, varicella oster, and toxoplasmosis in pregnanc . OBSTETRICS & GYNECOLOGY. 2015 Jun;125(6):1510-1525.

[4] Pamela Palasanthiran, Mike Starr, Cher l Jones and Michelle Giles. Management of Perinatal Infections. Australasian Societ for Infectious Diseases 2014.

[5] Teimouri, A., et al. "Role of Toxoplasma gondii IgG avidit testing in discriminating between acute and chronic toxoplasmosis in pregnanc ." Journal of Clinical Microbiolog (2020).

[6] P Rice. "C. tomealovirus (CMV) in pregnanc ." (2008).

[7] Emeritus Prof JE Banatvala FRCPATH, DWG Brown FRCPATH. "Rubella." The Lancet, Volume 363, Issue 9415, 3 April 2004, Pages 1127-1137